Related Experiment Video

Updated: Jul 15, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

The future of the new selective estrogen receptor modulators

Santiago Palacios1

  • 1Palacios Institute of Women's Health, Antonio Acuña 9, 28009 Madrid, Spain. ipalacios@institutopalacios.com

Menopause International
|April 24, 2007
PubMed

Insights

Selective estrogen receptor modulators (SERMs) offer mixed estrogen activity for postmenopausal women. Research aims to develop new SERMs that protect bones and prevent breast cancer without increasing risks of endometrial cancer, blood clots, or hot flashes.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Oncology

Background:

  • Selective estrogen receptor modulators (SERMs) exhibit dual estrogen agonist/antagonist properties.
  • Four SERMs (tamoxifen, toremifene, clomifene, raloxifene) are currently approved for clinical use.
  • Clinical trials like STAR and RUTH investigated SERMs for primary breast cancer and cardiovascular disease prevention in postmenopausal women.

Purpose of the Study:

  • To review the current landscape and future directions of SERM development.
  • To identify ideal characteristics for next-generation SERMs.
  • To explore the role of technological advancements in SERM research.

Main Methods:

  • Literature review of existing SERMs and clinical trial data (STAR, RUTH).
  • Discussion of ongoing research and evaluation of new-generation SERMs (bazedoxifene, arzoxifene, lasofoxifene, ospemifene).
  • Consideration of estrogen receptor activation studies.

Main Results:

  • Existing SERMs have demonstrated potential benefits but also associated risks.
  • Newer SERMs are under evaluation to optimize therapeutic profiles.
  • Technological progress in studying estrogen receptor activation is crucial for future drug discovery.

Conclusions:

  • The goal is to develop SERMs that offer skeletal protection and breast cancer prevention.
  • Future SERMs should minimize risks such as endometrial cancer, venous thromboembolism, and hot flashes.
  • Advancements in understanding estrogen receptor mechanisms are key to successful SERM development.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...